Faron Pharmaceuticals

The BEXMAB trial evaluates bexmarilimab combined with azacitidine and other hypomethylating agents for relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Bexmarilimab targets Clever-1 to reprogram macrophages, an emerging immunotherapy approach.

Faron facilitates participation in clinical trials for its drug candidates through treating physicians or hospitals.

Faron advances immunotherapy discoveries to disrupt cancer treatment, focusing on hematological malignancies and solid tumors.

The company explains that investigator-initiated trials (IITs) are an alternative model to company-sponsored trials in clinical development.

Faron Pharmaceuticals published its 2024 Annual Report, detailing its focus on novel immunotherapies for cancer.

Faron announced the final patient was identified for the BEXMAB Phase II study in myelodysplastic syndrome, with topline data expected in April 2025.

This webpage brings together Faron’s company announcements, press releases, and published reports and presentations in one place.

Faron’s public offering aimed to strengthen its cash position for key 2024 milestones, including a commercial partnering deal.

Faron offers career opportunities for professionals dedicated to transforming cancer care.

The Board of Faron emphasizes ethical corporate governance and supervises the company’s general affairs and business operations.

Faron is a Finnish limited liability company governed by the Finnish Limited Liability Companies Act and its Articles of Association.

Faron’s administration and control involve the shareholders, Board of Directors, and CEO, with the Management Team assisting the CEO in business operations.

Faron’s Scientific Advisory Board includes immunologists, oncologists, and industry professionals with experience in biotechnology and pharmaceutical R&D.

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer treatments that use the patient’s immune system. Its lead asset, bexmarilimab, is being tested in Phase I/II trials for hematological cancers.

Faron sets high standards for its operations, suppliers, and industry leadership in developing transformational cancer treatments.

Faron Pharmaceuticals Ltd is based in Turku, Finland, with contact details for investor relations, business development, and purchasing.

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer treatments using the patient’s immune system.